SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-120426
Filing Date
2022-04-26
Accepted
2022-04-26 17:02:13
Documents
15
Period of Report
2022-04-26
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d326489d8k.htm   iXBRL 8-K 36220
2 EX-3.1 d326489dex31.htm EX-3.1 8750
3 EX-99.1 d326489dex991.htm EX-99.1 12343
  Complete submission text file 0001193125-22-120426.txt   246669

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA bcacu-20220426.xsd EX-101.SCH 4849
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE bcacu-20220426_def.xml EX-101.DEF 15268
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE bcacu-20220426_lab.xml EX-101.LAB 25921
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE bcacu-20220426_pre.xml EX-101.PRE 16426
9 EXTRACTED XBRL INSTANCE DOCUMENT d326489d8k_htm.xml XML 7516
Mailing Address 280 PARK AVENUE, SUITE 43W NEW YORK NY 10017
Business Address 280 PARK AVENUE, SUITE 43W NEW YORK NY 10017 6466036716
Brookline Capital Acquisition Corp. (Filer) CIK: 0001814140 (see all company filings)

IRS No.: 851260244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39488 | Film No.: 22855201
SIC: 2836 Biological Products, (No Diagnostic Substances)